Wolfgang E. Schmidt

17.9k total citations · 2 hit papers
280 papers, 13.2k citations indexed

About

Wolfgang E. Schmidt is a scholar working on Surgery, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Wolfgang E. Schmidt has authored 280 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Surgery, 99 papers in Molecular Biology and 81 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Wolfgang E. Schmidt's work include Neuropeptides and Animal Physiology (74 papers), Diabetes Treatment and Management (60 papers) and Pancreatic function and diabetes (43 papers). Wolfgang E. Schmidt is often cited by papers focused on Neuropeptides and Animal Physiology (74 papers), Diabetes Treatment and Management (60 papers) and Pancreatic function and diabetes (43 papers). Wolfgang E. Schmidt collaborates with scholars based in Germany, Denmark and United States. Wolfgang E. Schmidt's co-authors include Juris J. Meier, Michael A. Nauck, Baptist Gallwitz, Jens J. Holst, Baptist Gallwitz, Rolf Mentlein, W. Creutzfeldt, John B. Buse, Ulrich R. Fölsch and Julio Rosenstock and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Wolfgang E. Schmidt

275 papers receiving 12.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

2009 1.2k citations John B. Buse, Giorgio Sesti et al. profile →
Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1993 966 citations Wolfgang E. Schmidt et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Wolfgang E. Schmidt	6.1k	4.8k	4.7k	2.4k	2.2k	280	13.2k
W. Creutzfeldt	9.0k 1.5×	9.1k 1.9×	4.8k 1.0×	2.9k 1.2×	2.9k 1.4×	403	17.4k
Burkhard Göke	6.4k 1.0×	6.1k 1.3×	6.0k 1.3×	1.8k 0.7×	4.1k 1.9×	423	20.1k
Steen Seier Poulsen	2.6k 0.4×	3.5k 0.7×	3.4k 0.7×	1.1k 0.5×	1.3k 0.6×	281	10.7k
John A. Wagner	2.1k 0.3×	1.5k 0.3×	5.9k 1.2×	2.5k 1.0×	1.5k 0.7×	250	13.8k
Philip W. Shaul	4.1k 0.7×	4.4k 0.9×	5.4k 1.1×	534 0.2×	1.2k 0.6×	211	18.7k
Marten H. Hofker	1.9k 0.3×	2.7k 0.6×	7.1k 1.5×	1.4k 0.6×	839 0.4×	203	15.2k
Masashi Mukoyama	1.5k 0.3×	1.7k 0.3×	4.5k 1.0×	889 0.4×	824 0.4×	259	15.3k
Derek LeRoith	9.3k 1.5×	1.9k 0.4×	8.0k 1.7×	514 0.2×	2.0k 0.9×	181	16.1k
Frans Schuit	3.6k 0.6×	6.5k 1.3×	5.2k 1.1×	477 0.2×	699 0.3×	177	13.3k
Phillip Görden	5.7k 0.9×	4.6k 0.9×	9.5k 2.0×	666 0.3×	1.8k 0.8×	286	20.2k

Countries citing papers authored by Wolfgang E. Schmidt

Since Specialization

Citations

This map shows the geographic impact of Wolfgang E. Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang E. Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang E. Schmidt more than expected).

Fields of papers citing papers by Wolfgang E. Schmidt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang E. Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang E. Schmidt. The network helps show where Wolfgang E. Schmidt may publish in the future.

Co-authorship network of co-authors of Wolfgang E. Schmidt

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang E. Schmidt. A scholar is included among the top collaborators of Wolfgang E. Schmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang E. Schmidt. Wolfgang E. Schmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gambichler, Thilo, et al.. (2025). Liver Scores in the Prognostication of COVID-19 Patients. Viruses. 17(3). 444–444.

Gambichler, Thilo, Marina Skrygan, Laura Susok, et al.. (2024). A Prospective Study Investigating Immune Checkpoint Molecule and CD39 Expression on Peripheral Blood Cells for the Prognostication of COVID-19 Severity and Mortality. Viruses. 16(5). 810–810. 2 indexed citations

Kov́acs, Árṕad, Saltanat Zhazykbayeva, Melissa Herwig, et al.. (2024). Sex-specific cardiovascular remodeling leads to a divergent sex-dependent development of heart failure in aged hypertensive rats. GeroScience. 46(5). 4543–4561. 4 indexed citations

Zhazykbayeva, Saltanat, Melissa Herwig, Heidi Budde, et al.. (2023). Oxidative stress and inflammation distinctly drive molecular mechanisms of diastolic dysfunction and remodeling in female and male heart failure with preserved ejection fraction rats. Frontiers in Cardiovascular Medicine. 10. 1157398–1157398. 6 indexed citations

Gambichler, Thilo, Laura Susok, Jürgen C. Becker, et al.. (2023). Prognostic Performance of Inflammatory Biomarkers Based on Complete Blood Counts in COVID-19 Patients. Viruses. 15(9). 1920–1920. 11 indexed citations

Meister, Toni Luise, Yannick Brüggemann, Natalie Heinen, et al.. (2022). Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients. The Journal of Infectious Diseases. 226(9). 1608–1615. 20 indexed citations

Bulut, Kerem, Antoaneta A. Markova, Ali Canbay, Wolfgang E. Schmidt, & Alişan Kahraman. (2022). Whipple’s disease – a rare and challenging complication in a patient with Crohn’s disease. Zeitschrift für Gastroenterologie. 60(4). 598–601. 2 indexed citations

Schultheis, Beate, Dirk Reuter, M. Ebert, et al.. (2017). Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Annals of Oncology. 28(10). 2429–2435. 97 indexed citations

Fensterer, H, Carmen Schade‐Brittinger, Hans‐Helge Müller, et al.. (2013). Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Annals of Oncology. 24(10). 2576–2581. 28 indexed citations

10.

Schmidt, Wolfgang E., Jens Sandahl Christiansen, Mette Hammer, Marcin Zychma, & John B. Buse. (2011). Patient‐reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open‐label study. Diabetic Medicine. 28(6). 715–723. 30 indexed citations

11.

Löhr, Matthias, Stephan Haas, Wolf O. Bechstein, et al.. (2011). Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Annals of Oncology. 23(5). 1214–1222. 80 indexed citations

12.

Armstrong, Matthew J., et al.. (2010). High prevalence of advanced NAFLD in type 2 diabetic patients with unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-analysis of the LEAD Program. Diabetologia. 53. 1 indexed citations

13.

Armstrong, Matthew J., A Falahati, Oscar Ö. Braun, et al.. (2010). High Prevalence of Advanced NAFLD in Type 2 Diabetic Patients with Normal Liver Enzymes and Effect of Liraglutide on NAFLD: Meta-Analysis of the LEAD Program. Diabetes. 59. 4 indexed citations

14.

Seeliger, Stephan, Joerg Buddenkotte, Anjona Schmidt‐Choudhury, et al.. (2010). Pituitary Adenylate Cyclase Activating Polypeptide. American Journal Of Pathology. 177(5). 2563–2575. 61 indexed citations

15.

Schmidt, Wolfgang E., Stephen Gough, Sten Madsbad, et al.. (2009). Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss. Diabetologia. 52. 5 indexed citations

16.

Otte, Jan‐Michel, et al.. (2008). Probiotics Regulate the Expression of COX-2 in Intestinal Epithelial Cells. Nutrition and Cancer. 61(1). 103–113. 60 indexed citations

17.

Bulut, Kerem, et al.. (2008). Increased duodenal expression of transforming growth factor-α and epidermal growth factor during experimental colitis in rats. European Journal of Gastroenterology & Hepatology. 20(10). 989–994. 5 indexed citations

18.

Yu, Honggang, Yanning Yang, Hesheng Luo, et al.. (2003). Increased Expression of RelA/Nuclear Factor-κB Protein Correlates with Colorectal Tumorigenesis. Oncology. 65(1). 37–45. 97 indexed citations

19.

Arlt, Alexander, et al.. (2001). Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 20(7). 859–868. 196 indexed citations

20.

Nees, S., Wolfgang E. Schmidt, & F Schneider. (1971). [Chemical modification and catalytic activity of carbonate-hydro-lyase B from bovine erythrocytes. Modification of arginine, histidine, lysine, tyrosine and tryptophan].. PubMed. 352(3). 355–68. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact